Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

The use of natalizumab for multiple sclerosis.

Brandstadter R, Katz Sand I.

Neuropsychiatr Dis Treat. 2017 Jun 28;13:1691-1702. doi: 10.2147/NDT.S114636. eCollection 2017. Review.

2.

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis.

Freedman MS, Wolinsky JS, Truffinet P, Comi G, Kappos L, Miller AE, Olsson TP, Benamor M, Chambers S, O'Connor PW.

Mult Scler J Exp Transl Clin. 2015 Dec 7;1:2055217315618687. doi: 10.1177/2055217315618687. eCollection 2015 Jan-Dec.

3.

Natalizumab in Multiple Sclerosis: Long-Term Management.

Clerico M, Artusi CA, Liberto AD, Rolla S, Bardina V, Barbero P, Mercanti SF, Durelli L.

Int J Mol Sci. 2017 Apr 29;18(5). pii: E940. doi: 10.3390/ijms18050940. Review.

4.

Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation.

González-Suarez I, Rodríguez de Antonio L, Orviz A, Moreno-García S, Valle-Arcos MD, Matias-Guiu JA, Valencia C, Jorquera Moya M, Oreja-Guevara C.

Brain Behav. 2017 Mar 14;7(4):e00671. doi: 10.1002/brb3.671. eCollection 2017 Apr.

5.

Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis.

Calkwood J, Vollmer T, Fox RJ, Zhang R, Novas M, Sheikh SI, Viglietta V.

Int J MS Care. 2016 May-Jun;18(3):138-46. doi: 10.7224/1537-2073.2015-020.

6.

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Spelman T, Kalincik T, Jokubaitis V, Zhang A, Pellegrini F, Wiendl H, Belachew S, Hyde R, Verheul F, Lugaresi A, Havrdová E, Horáková D, Grammond P, Duquette P, Prat A, Iuliano G, Terzi M, Izquierdo G, Hupperts RM, Boz C, Pucci E, Giuliani G, Sola P, Spitaleri DL, Lechner-Scott J, Bergamaschi R, Grand'Maison F, Granella F, Kappos L, Trojano M, Butzkueven H.

Neurol Clin Pract. 2016 Apr;6(2):102-115.

7.
8.

An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations.

Kornek B.

Patient Prefer Adherence. 2015 May 19;9:675-84. doi: 10.2147/PPA.S20791. eCollection 2015. Review.

9.

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.

O'Connor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick RA, Hauswirth K, Cristiano LM, Forrestal F, Duda P.

Neurology. 2014 Jul 1;83(1):78-86. doi: 10.1212/WNL.0000000000000541. Epub 2014 Jun 4. Erratum in: Neurology. 2014 Aug 19;83(8):773.

10.

Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.

Hoepner R, Faissner S, Salmen A, Gold R, Chan A.

J Cent Nerv Syst Dis. 2014 Apr 28;6:41-9. doi: 10.4137/JCNSD.S14049. eCollection 2014. Review.

11.

Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life.

Planas R, Martin R, Sospedra M.

Patient Relat Outcome Meas. 2014 Apr 4;5:25-33. doi: 10.2147/PROM.S41768. eCollection 2014. Review.

12.

Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring.

Alroughani RA, Aref HM, Bohlega SA, Dahdaleh MP, Feki I, Al Jumah MA, Al-Kawi MZ, Koussa SF, Sahraian MA, Alsharoqi IA, Yamout BI.

BMC Neurol. 2014 Feb 12;14:27. doi: 10.1186/1471-2377-14-27. Review.

13.

New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.

Nicholas J, Morgan-Followell B, Pitt D, Racke MK, Boster A.

J Cent Nerv Syst Dis. 2012 May 16;4:81-103. doi: 10.4137/JCNSD.S6692. Print 2012.

14.

Natalizumab therapy for multiple sclerosis.

Chataway J, Miller DH.

Neurotherapeutics. 2013 Jan;10(1):19-28. doi: 10.1007/s13311-012-0171-4. Review.

15.

Interferon beta and glatiramer acetate therapy.

McGraw CA, Lublin FD.

Neurotherapeutics. 2013 Jan;10(1):2-18. doi: 10.1007/s13311-012-0163-4. Review.

16.

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.

Boster A, Bartoszek MP, O'Connell C, Pitt D, Racke M.

Ther Adv Neurol Disord. 2011 Sep;4(5):319-32. doi: 10.1177/1756285611422108.

17.

Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab.

Patti F, Pappalardo A.

Clinicoecon Outcomes Res. 2009;1:45-51. Epub 2009 Aug 21.

18.

New approaches in the management of multiple sclerosis.

Barten LJ, Allington DR, Procacci KA, Rivey MP.

Drug Des Devel Ther. 2010 Nov 24;4:343-66. doi: 10.2147/DDDT.S9331. Review.

Supplemental Content

Support Center